Researchers Hunt for Biomarkers to Guide Chemo-Free Neoadjuvant Treatment for HER2-Positive Cancers
As precision oncology advances, researchers are intensifying efforts to identify reliable biomarkers that can predict which patients with HER2-positive breast cancer can safely avoid chemotherapy during neoadjuvant (pre-surgical) treatment. The goal is to spare eligible patients from the toxic side effects of chemotherapy while maintaining high rates of pathological complete response (pCR) — a strong predictor of long-term survival. This shift toward chemo-free regimens relies on a deeper understanding of tumor biology and the development of predictive tools grounded in clinical evidence.
Why Biomarkers Matter in HER2-Positive Breast Cancer
HER2-positive breast cancer, which accounts for about 15–20% of all breast cancers, is characterized by overexpression of the HER2 protein, driving aggressive tumor growth. Historically, treatment has combined anti-HER2 therapies — such as trastuzumab and pertuzumab — with chemotherapy to maximize tumor shrinkage before surgery. While effective, this approach exposes patients to significant short- and long-term toxicities, including fatigue, neuropathy, cardiotoxicity and increased risk of secondary malignancies.
Recent clinical trials have demonstrated that dual anti-HER2 blockade alone can achieve high pCR rates in select patients, raising the possibility of chemotherapy omission. However, not all tumors respond equally, and identifying who can safely forgo chemo requires precise biomarkers that reflect tumor sensitivity to targeted therapy.
Promising Biomarker Candidates Under Investigation
Several biomarker strategies are being explored to guide treatment de-escalation in HER2-positive disease:
1. Tumor-Infiltrating Lymphocytes (TILs)
High levels of TILs — immune cells present within the tumor microenvironment — have consistently correlated with better response to anti-HER2 therapy and higher pCR rates. A meta-analysis published in The Lancet Oncology found that patients with TILs ≥50% had significantly improved outcomes with dual HER2-targeted therapy alone. Researchers are now validating TIL assessment as a routine, reproducible biomarker in clinical trials such as the PAMELA trial and TRIO-US B07.
2. Hormone Receptor Status
HER2-positive, hormone receptor-negative (HR−) tumors tend to be more immunogenic and responsive to targeted therapy. In contrast, HR+/HER2+ tumors often exhibit lower pCR rates to anti-HER2 monotherapy, suggesting they may still require chemotherapy. Studies like PHERGain have shown that HR− status, combined with high TILs, identifies a subgroup with excellent chemotherapy-free outcomes.
3. Genomic and Transcriptomic Signatures
Researchers are employing RNA sequencing and AI-driven platforms to identify gene expression profiles predictive of chemo-free response. For example, the HER2-enriched (HER2-E) subtype, defined by specific transcriptional patterns, has been linked to superior outcomes with dual HER2 blockade. Ongoing function aims to refine these signatures into clinically applicable assays.
4. Minimal Residual Disease (MRD) Monitoring
While not predictive upfront, sensitive MRD assays using circulating tumor DNA (ctDNA) are being studied to assess early treatment response. A rise in ctDNA during therapy may signal resistance, prompting early intervention. Trials like DIRECT are evaluating whether ctDNA dynamics can guide adaptive treatment strategies, potentially sparing chemo in molecularly responsive patients.
Clinical Trials Shaping the Future
Several landmark trials are testing chemo-free neoadjuvant regimens:
- PAMELA (NCT01829048): This phase II trial showed that dual HER2 blockade with trastuzumab and pertuzumab achieved a pCR rate of 43% in all comers and 57% in HR−/HER2+ patients. High TILs further enriched for response.
- TRIO-US B07 (NCT02419546): Evaluating dual blockade plus endocrine therapy in HR+/HER2+ disease, this trial seeks to determine if adding hormonal therapy can improve outcomes without chemo.
- ADAPT (NCT02926156): Using an adaptive design, this trial adjusts therapy based on early radiological and biomarker response, aiming to identify who can safely avoid chemo.
- ComPARE (NCT03624823): Investigating whether trastuzumab deruxtecan (T-DXd), a potent antibody-drug conjugate, can replace chemotherapy in high-risk HER2+ disease.
Results from these studies are informing updated guidelines. The National Comprehensive Cancer Network (NCCN) now acknowledges that select patients may be candidates for chemo-free neoadjuvant therapy in clinical trial settings, with biomarker selection being critical to patient selection.
Challenges and Considerations
Despite promise, challenges remain:
- Assay Standardization: TIL evaluation varies across laboratories; efforts are underway to harmonize scoring methods through initiatives like the TILs in Breast Cancer Working Group.
- Tumor Heterogeneity: Biomarker expression can differ within a tumor or change over time, necessitating multi-region or liquid biopsy approaches.
- Long-Term Data: While pCR is a strong surrogate endpoint, definitive proof that chemo-free regimens improve overall survival requires longer follow-up from ongoing trials.
Experts emphasize that biomarker-guided treatment should not replace shared decision-making. Patients must be fully informed of the potential benefits and risks, including the little but real chance of residual disease if chemo is omitted.
The Road Ahead: Toward Truly Personalized Therapy
The future of HER2-positive breast cancer treatment lies in integrating multiple biomarkers — immune, hormonal, genomic, and dynamic — into composite predictive scores. Artificial intelligence and machine learning are being applied to multimodal data from imaging, pathology, and blood tests to refine risk stratification.
As Dr. Jennifer Litton, Professor of Breast Medical Oncology at MD Anderson Cancer Center, noted in a recent interview: “We’re moving away from a one-size-fits-all approach. The goal is to use biomarkers to identify who truly needs chemotherapy and who can be spared — not just to reduce toxicity, but to deliver smarter, more effective care.”
With several trials expected to report mature results in the next 2–3 years, the field is on the cusp of a paradigm shift. For eligible patients, chemo-free neoadjuvant therapy could soon become a standard option — guided not by intuition, but by validated, biologically grounded biomarkers.
Key Takeaways
- Biomarkers such as tumor-infiltrating lymphocytes (TILs), hormone receptor status, and genomic signatures are being validated to identify HER2-positive breast cancer patients who may safely avoid chemotherapy before surgery.
- High TILs (≥50%) and HR− status are strongly associated with excellent pathological complete response rates to dual HER2-targeted therapy alone.
- Ongoing clinical trials (PAMELA, TRIO-US B07, ADAPT, ComPARE) are testing chemo-free regimens and refining biomarker-guided strategies.
- Challenges include standardizing biomarker assays, addressing tumor heterogeneity, and confirming long-term survival benefits.
- The ultimate goal is personalized treatment: using biomarkers to escalate or de-escalate therapy based on individual tumor biology, improving both outcomes and quality of life.